RecruitingNCT04843111

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

The MenQuadfi® Pregnancy Registry: A Surveillance Registry to Assess the Safety of MenQuadfi® Among Exposed Pregnant Women and Their Offspring

Sponsor

Sanofi Pasteur, a Sanofi Company

Enrollment

50 participants

Start Date

Mar 5, 2021

Study Type

OBSERVATIONAL

Conditions

Meningococcal Infection

Summary

Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine for people with meningococcal infection. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMeningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine

Pharmaceutical form: Solution for injection Route of administration: Intramuscular

Locations(1)

Pennsylvania Locations

Swiftwater, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04843111

Related Trials

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

NCT071359862 locations